Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Inventiva S.A.    IVA   FR0013233012

INVENTIVA S.A.

(IVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
15.56(c) 14.9(c) 13.9(c) 13.68(c) 12.9 Last
107 144 154 994 150 111 126 636 215 290 Volume
+1.30% -4.24% -6.71% -1.58% -5.70% Change
More quotes
Financials
Sales 2020 3,49 M 4,22 M 4,22 M
Net income 2020 -32,6 M -39,5 M -39,5 M
Net cash position 2020 110 M 134 M 134 M
P/E ratio 2020 -13,6x
Yield 2020 -
Sales 2021 49,6 M 60,0 M 60,0 M
Net income 2021 -46,3 M -56,1 M -56,1 M
Net cash position 2021 92,5 M 112 M 112 M
P/E ratio 2021 -10,3x
Yield 2021 -
Capitalization 525 M 639 M 635 M
EV / Sales 2020 119x
EV / Sales 2021 8,72x
Nbr of Employees 86
Free-Float 91,9%
More Financials
Company
Inventiva S.A. is a biopharmaceutical company specialized in the treatment of diseases in the fields of fibrosis, lysosomal overload and oncology. The group is developing two drug candidates - lanifibranor and odiparcil - in non-alcoholic steatohepatitis (« NASH ») and mucopolysaccharidosis (« MPS ») respectively, as well as a portfolio of several programs in the preclinical stage. Lanifibranor is currently in Phase... 
More about the company
Notations Surperformance© of Inventiva S.A.
Trading Rating : Investor Rating :
More Ratings
All news about INVENTIVA S.A.
01/15INVENTIVA S A : Half-Year Review of Inventiva's Liquidity Contract with Kepler C..
AQ
01/06INVENTIVA S A : to present at the 39th Annual J.P. Morgan Healthcare Conference
PU
01/06INVENTIVA S A : annonce sa participation à la « 39th Annual J.P. Morgan Healthca..
GL
01/06INVENTIVA S A : Présentation corporate janvier 2021
PU
01/06INVENTIVA S A : to Kick Off Phase Three Trial for Lanifibranor in Non-Alcoholic ..
MT
01/05INVENTIVA S A : Moving Ahead With Phase III Trial of Prospective Treatment for L..
MT
01/05Inventiva announces design of Phase III clinical trial with lanifibranor in N..
GL
2020INVENTIVA S A : announces the publication in the Journal of Hepatology of new pr..
GL
2020INVENTIVA : to participate at the Piper Sandler 32nd Annual Virtual Healthcare C..
AQ
2020INVENTIVA : to participate at the Piper Sandler 32nd Annual Virtual Healthcare C..
AQ
2020INVENTIVA S A : to participate at the Piper Sandler 32nd Annual Virtual Healthca..
GL
2020INVENTIVA : - Q3 2020 Financial Information
AQ
2020INVENTIVA S A : Q3 2020 Revenues and Cash Position
PU
2020INVENTIVA S A : Q3 2020 Financial Information
PU
2020INVENTIVA S A : Q3 2020 Financial Information
AQ
More news
News in other languages on INVENTIVA S.A.
01/15INVENTIVA S A : Bilan semestriel du contrat de liquidité de la société Inventiva..
01/07EN DIRECT DES MARCHES : Saint-Gobain, Dassault, Pierre & Vacances, SMCP, DBV, La..
01/07Jusqu'à la lie
01/06INVENTIVA S A : annonce sa participation à la « 39th Annual J.P. Morgan Healthca..
01/06INVENTIVA S A : annonce sa participation à la « 39th Annual J.P. Morgan Healthca..
More news
Chart INVENTIVA S.A.
Duration : Period :
Inventiva S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 28,19 €
Last Close Price 13,68 €
Spread / Highest target 236%
Spread / Average Target 106%
Spread / Lowest Target -19,6%
EPS Revisions
Managers and Directors
NameTitle
Frédéric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial & Administrative Officer
Pierre Broqua Director, Deputy CEO & Chief Scientific Officer
Michael P. Cooreman Chief Medical Officer
Chris Buyse Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INVENTIVA S.A.16.72%639
GILEAD SCIENCES, INC.14.49%83 610
WUXI APPTEC CO., LTD.36.65%64 891
VERTEX PHARMACEUTICALS0.55%61 795
REGENERON PHARMACEUTICALS12.62%57 427
BEIGENE, LTD.38.68%32 675